Medical Devices & Diagnostics Archives - Page 47 of 82

What Roche’s $1.05bn PathAI move reveals about the future of pathology labs

Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.

Microsure has European clearance for MUSA-3. Now hospitals must decide whether robotic microsurgery can justify adoption.

Wearable CGMs dominate diabetes care. Glucotrack’s implantable CBGM now faces the harder FDA test: durable blood-based proof.

X-rays dominate fracture triage. Rivanna’s FDA-cleared Accuro XV tests whether ultrasound can move closer to the front line.

Bladder testing needs better real-world data. Bright Uro’s FDA-cleared sensor may push urodynamics beyond catheter-heavy workflows.

Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.

NUT carcinoma has few options and poor survival. Wenda Pharma’s NHWD-870 may test how fast China can move rare oncology forward.

Greener inhalers need more than lower-carbon chemistry. Aptar Pharma’s FDA-backed work tests the science regulators may need.

Molecular testing is powerful but lab-bound. Seek Labs’ patent raises a sharper question: can point-of-care diagnostics finally scale?

Heart failure care needs faster decongestion without kidney harm. Reprieve’s FASTR data now face the pivotal trial test.